Completed PHASE3 INTERVENTIONAL 2-arm NCT01010100

Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care

A Multi-centre, Parallel, Double-blind, Randomised and Placebo Controlled Spanish Study, to Prevent or Delay the Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care (PREDIAP)

Sponsor: Bayer

Conditions Diabetes Mellitus

Interventions Acarbose (Glucobay, BAYG5421) Placebo

Updated 6 times since 2017 Last updated: Dec 23, 2010 Started: Aug 31, 2000 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diabetes Mellitus and is currently completed. Bayer leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Agost, Spain , Alicante, Spain , Begonte, Spain , Camas, Spain , Constantí, Spain , Cornudella, Spain , Crevillent, Spain , Falset, Spain , Madrid, Spain , Novelda, Spain and 10 more locations